ResMed Inc.

Based on a comprehensive analysis of ResMed (RMD), the stock presents a compelling case for long-term investors, balanced by some near-term valuation concerns.

Analysis Summary: RMD is a fundamentally strong company with impressive revenue growth, expanding profit margins, and a rock-solid balance sheet with minimal debt. Its operations are profitable and efficient. Technically, the stock is in a period of stabilization after past volatility, currently trading in a neutral position within its 52-week range. However, its valuation metrics are elevated, trading at a premium to the market, which may limit near-term upside potential. The primary risks are industry-specific, such as competition and regulation, rather than financial distress.

Buy Recommendation: ResMed is a high-quality company worth buying for long-term growth investors. Its strong fundamentals, market leadership, and financial health provide a solid foundation. While the current premium valuation suggests it may be prudent to accumulate shares on any market-driven pullbacks, the company's consistent execution justifies a strategic allocation for those focused on durable growth in the healthcare sector.

RockFlow Model Forecast: Three Scenarios for 2026

Based on a comprehensive analysis, here is a 12-month outlook for ResMed (RMD):

12-Month Outlook for RMD

ResMed's primary positive catalysts for the next year are its consistent execution, market leadership in the sleep apnea and respiratory care sector, and the ongoing integration of digital health solutions, which should continue to drive revenue growth and margin expansion. The key risk remains its premium valuation, which makes the stock susceptible to a pullback if quarterly results merely meet, rather than exceed, high market expectations, or if broader market multiples contract. Secondary risks include increased competition and potential regulatory changes affecting reimbursement rates. While a specific analyst target is not provided, the elevated valuation suggests near-term upside may be tempered, with a realistic trading range likely between $230 and $280, assuming steady execution without major negative surprises.

Wall Street Consensus

Most Wall Street analysts are optimistic about ResMed Inc.'s 12-month outlook, with consensus target around $256.26, indicating expected upside potential.

Overall, RMD has investment potential but also faces challenges. Here are key factors to weigh before investing.

Overall Assessment: RMD's stock presents a mixed performance profile, with marginal gains over the recent quarter but slight underperformance against the broader market, indicating a period of relative stabilization after a more volatile year.

Short-term Performance: The stock's 1-month decline of -1.09% contrasts with its modest 3-month gain of 1.66%, suggesting recent weakness after a positive quarter. Despite the positive quarterly return, RMD has underperformed its market benchmark by -2.04% over the same 3-month period, highlighting a recent lag in relative strength. The stock's beta below 1.0 confirms its lower volatility compared to the market, which is consistent with its muted short-term moves.

Current Position: Trading at $254.90, RMD sits near the midpoint (approximately 49%) of its 52-week range ($199.92 to $293.81), indicating it is neither overbought nor oversold from a technical perspective. This neutral positioning aligns with the stock's recovery from a significant 1-year maximum drawdown of -18.0%, suggesting it has stabilized but lacks strong directional momentum.

Revenue & Profitability RMD demonstrated solid revenue growth, increasing from $1.34 billion in Q1 to $1.42 billion in Q2. Profitability improved notably, with net income rising from $348.5 million to $392.6 million and net profit margin expanding from 26.1% to 27.6%. The company’s operating margin also strengthened, reflecting efficient cost management and operational leverage.

Financial Health The company maintains a strong financial position, evidenced by a low debt-to-equity ratio of 0.16 and robust liquidity with a current ratio of 3.06. Operating cash flow remains healthy, supporting ample coverage of debt obligations and capital expenditure needs. Interest coverage of 62.6x indicates negligible financial risk from debt servicing.

Operational Efficiency RMD exhibits solid operational efficiency, with a return on equity of 6.2% and an asset turnover of 0.17. While inventory turnover remains moderate at 0.58, fixed asset turnover of 1.95 suggests effective utilization of long-term assets. The company’s cash conversion cycle of 174.7 days highlights room for improvement in working capital management.

**Valuation Level**

ResMed's TTM P/E of 25.2 and forward P/E of 22.5 suggest a premium valuation relative to the broader market, indicating investors are paying a significant price for its current and expected earnings. This view is reinforced by a high PEG ratio of approximately 1.72, which signals the stock may be overvalued when its earnings growth is factored in, as a PEG above 1.0 often suggests a rich valuation. The exceptionally high EV/EBITDA of 61.6 further confirms that the company's enterprise value is lofty compared to its core operational profitability.

**Peer Comparison**

Without specific industry average data, a conclusive peer comparison cannot be performed. However, the valuation metrics presented, particularly the high EV/EBITDA and P/B ratio of 5.92, are typically associated with growth-oriented or technology-focused sectors. To determine if ResMed is fairly valued, a comparison against the precise P/E, P/B, and EV/EBITDA averages for the Medical Devices/Equipment industry would be essential.

ResMed's volatility risk appears moderate, evidenced by a Beta of 0.877, indicating the stock is slightly less volatile than the broader market. The maximum drawdown of -18.0% over the past year is notable but not extreme, suggesting that while shareholders have experienced significant declines from peak values, the downside has been contained relative to more high-beta equities.

Other risks do not include significant short interest, which implies a lack of strong negative sentiment from sophisticated investors. Liquidity risk is also low due to the stock's high trading volume and large market capitalization. The primary risks are more likely fundamental, such as competitive pressures in the sleep apnea device market and potential regulatory changes affecting medical device reimbursement.